A Study to Evaluate White Matter Hyperintensities in Migraine
NCT ID: NCT05112289
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
50 participants
INTERVENTIONAL
2021-08-16
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
NCT06132529
Volumetric MRI Brain in Patients With Migraine
NCT06077448
fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?
NCT00868556
Longitudinal Study of the Patients With Medication-overuse Headache or Migraine That Completed Baseline MRI
NCT05528081
The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine
NCT03418766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Migraine cohort
Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
Brain Neuroimaging
Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Small vessel ischemic (SVI) disease cohort
Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
Brain Neuroimaging
Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Multiple sclerosis (MS) cohort
Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
Brain Neuroimaging
Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brain Neuroimaging
Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 20-45 years.
* Presence of WMH on MRI.
* Female only
* Ages \> 60 years.
* Presence of WMH on MRI.
* Female only.
* Ages 20-45.
* Presence of WMH on MRI.
Exclusion Criteria
* History of cancer or organ transplantation.
* Contraindication to MRI.
* Pregnancy.
* History of abnormal brain MRI other than WMH.
* Subjects not willing to comply with the study procedures will be removed from the study.
* History of migraine and/or history of MS or other neurological disease other than SVI.
* History of cancer or organ transplantation.
* History of abnormal brain MRI other than WMH.
* Pregnancy.
* History of abnormal brain MRI other than WMH.
* Subjects not willing to comply with the study procedures will be removed from the study.
* History of migraine and/or history of SVI or other neurological disease other than MS.
* History of cancer or organ transplantation.
* History of abnormal brain MRI other than WMH.
* Pregnancy.
* History of abnormal brain MRI other than WMH.
* Subjects not willing to comply with the study procedures will be removed from the study.
20 Years
59 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Catherine (Cat) Chong
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Chong, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-006203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.